Dr. Piccart on the Importance of De-Escalation in Early Breast Cancer

Martine Piccart, MD, PhD
Published: Friday, Mar 17, 2017



Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses the importance of de-escalating treatment in early-stage breast cancer.

Historically, drug treatment in breast cancer has been aggressive and many patients are being overtreated, says Piccart. Systemic treatment plays a fundamental role in breast cancer, but there is substantial amount of evidence that shows only a small population of women benefit from escalating therapy.

The surgical and radiation fields, Piccart adds, have heavily focused on de-escalating therapy in selected women over the past few years, resulting in less mastectomies and axillary dissections, and shorter periods of radiation with successful outcomes.

<<< View more from the St. Gallen's Breast Cancer Conference


Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses the importance of de-escalating treatment in early-stage breast cancer.

Historically, drug treatment in breast cancer has been aggressive and many patients are being overtreated, says Piccart. Systemic treatment plays a fundamental role in breast cancer, but there is substantial amount of evidence that shows only a small population of women benefit from escalating therapy.

The surgical and radiation fields, Piccart adds, have heavily focused on de-escalating therapy in selected women over the past few years, resulting in less mastectomies and axillary dissections, and shorter periods of radiation with successful outcomes.

<<< View more from the St. Gallen's Breast Cancer Conference

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x